Retatrutide vs Semaglutide: Receptor Pharmacology and Clinical Research Compared

How retatrutide and semaglutide differ in receptor targets, molecular design and the depth of their published trial records. Laboratory reference.

By Updated

Semaglutide activates one receptor. Retatrutide activates three, and one of the three is the receptor the field spent two decades deliberately avoiding. That is the pharmacological distinction, and it is the only distinction this page draws between them.

There is a second distinction that matters just as much and is not pharmacological at all: the two compounds sit at opposite ends of the evidence spectrum. Semaglutide has reported hard clinical-outcome trials in tens of thousands of participants. Retatrutide has reported its first phase 3 result. Comparing the two therefore means comparing records of very different depth, and the page says so rather than flattening the difference.

What they are

PropertyRetatrutideSemaglutide
Development codeLY3437943NN9535
Compound typeSynthetic modified peptideSynthetic acylated peptide analogue of human GLP-1
Peptide familyGlucagon / secretin peptide superfamily (GIP, GLP-1 and glucagon receptor ligands)Glucagon / secretin peptide superfamily (GLP-1 receptor ligands)
Primary targetGlucose-dependent insulinotropic polypeptide receptor (GIPR)Glucagon-like peptide-1 receptor (GLP-1R)
Secondary targetsGlucagon-like peptide-1 receptor (GLP-1R), Glucagon receptor (GCGR)Not established
Receptor familyClass B1 (secretin-like) G protein-coupled receptorsClass B1 (secretin-like) G protein-coupled receptors
Agonist / antagonistAgonist at all three receptorsAgonist at the GLP-1 receptor
Highest research phasePhase 3 (completed and reported)Approved; phase 3 programmes and cardiovascular and kidney outcome trials completed and reported
Regulatory status (United States)Not approved. Retatrutide is an investigational compound and has not been approved by the U.S. Food and Drug Administration for any indication.Approved as a finished pharmaceutical product. Semaglutide is the active ingredient of products approved by the U.S. Food and Drug Administration and marketed by Novo Nordisk. That approval attaches to those finished products as manufactured, formulated and labelled by their sponsor. It does not attach to semaglutide as a chemical, and it confers nothing on research-grade material supplied for laboratory use.
Human trials publishedYesYes

Every value in this table is read from the two compounds’ own library entries when the site is built, so it cannot disagree with them. Nothing here ranks one compound against the other.

Semaglutide is an acylated analogue of human glucagon-like peptide-1, developed by Novo Nordisk and first described in the peer-reviewed literature in 2015 [1]. It is a single-receptor agonist at the glucagon-like peptide-1 receptor and is an approved medicine in the United States in defined indications.

Retatrutide is a synthetic 39-residue peptide developed by Eli Lilly and Company under the code LY3437943, first described in 2022. It is a single molecule with agonist activity at three class B1 G protein-coupled receptors: GIPR, GLP-1R and GCGR [2]. It is investigational and has not been approved by the U.S. Food and Drug Administration for any indication.

The two share one design idea and differ in everything built on top of it. The shared idea is albumin binding: both carry a fatty acid attached through a linker to a lysine side chain, and both are stabilised against dipeptidyl peptidase-4, so both persist in plasma long enough for a once-weekly schedule [1, 2]. Semaglutide's discovery paper is unusually explicit about the trade this involves — receptor affinity was deliberately sacrificed to buy albumin affinity, giving a molecule that is unremarkable at its receptor and extraordinary in residence time [1].

Receptor and mechanistic differences

The GLP-1 receptor is the shared target. It is a class B1, secretin-like G protein-coupled receptor that signals through Gs to raise intracellular cyclic AMP, expressed on pancreatic islet cells — where activation modulates glucose-dependent insulin secretion — and at sites in the central nervous system involved in the regulation of food intake [1, 4]. Semaglutide engages this receptor and nothing else.

Retatrutide engages it too, and adds two more. The GIP receptor is the second incretin receptor, also class B1 and also Gs-coupled, expressed in pancreatic islets and widely in peripheral organs and the brain [5]. The glucagon receptor is the third, cloned in 1993 and expressed most consequentially in liver [6]. Glucagon receptor signalling raises whole-body metabolic rate, and it also raises blood glucose when unopposed — which is precisely why glucagon agonism was historically excluded from diabetes research. The reported premise of the tri-agonist design is that the two incretin arms offset that glycaemic liability inside the same molecule [2].

So the mechanistic difference is not that retatrutide is a more potent GLP-1 receptor agonist. It is that retatrutide recruits two additional signalling routes in two additional tissue compartments, one of which acts in the opposite direction on glucose from the other two.

Receptors engaged
Semaglutide — GLP-1R only. Retatrutide — GIPR, GLP-1R and GCGR [1, 2].
Receptor family
Both act only at class B1 G protein-coupled receptors, all Gs-coupled [4, 2].
Design trade-off
Semaglutide accepted approximately three-fold lower GLP-1 receptor affinity than liraglutide in exchange for much higher albumin affinity [1]. Retatrutide's tunable parameter is the balance between three receptor activities rather than one affinity [2].
Reported half-life
Semaglutide, approximately one week in humans, supported by mini-pig pharmacokinetics [1]. Retatrutide, approximately six days in early clinical study [3].
Regulatory position
Semaglutide is approved in the United States in defined indications. Retatrutide is not approved for anything.

What the research compares

No trial has randomised participants between retatrutide and semaglutide. There is no head-to-head study of the two, and none is reported in the published retatrutide programme. The retatrutide phase 2 trial in type 2 diabetes used dulaglutide 1.5 mg as its active comparator [14]; every other published retatrutide trial has been placebo-controlled [13, 19]. Semaglutide has been compared head-to-head with tirzepatide in two trials [11, 18], but not with retatrutide.

There is a second asymmetry that no cross-trial arithmetic can bridge. Semaglutide's record includes cardiovascular and kidney outcome trials — SUSTAIN-6, SELECT and FLOW — that counted deaths, myocardial infarctions, strokes and kidney failure in populations of 3,297, 17,604 and 3,533 participants respectively [7, 12, 15]. Retatrutide has reported no outcome trial of any kind. Its published endpoints are laboratory and anthropometric measures over 12 to 48 weeks, plus one 40-week phase 3 glycaemic endpoint [3, 13, 19].

A surrogate endpoint and a clinical outcome are different categories of evidence, not different sizes of the same evidence. Published systematic analyses of approved incretin mimetics make the related point about indirect comparison generally: setting results from separate placebo-controlled trials against one another rests on assumptions that head-to-head randomisation does not require [23].

What the human research shows for each

Human clinical research

Results from pharmaceutical clinical trials describe the investigational material and populations used in those studies and should not be interpreted as establishing the effects of research-grade materials offered for laboratory use.

Semaglutide — outcome trials and surrogate trials

SUSTAIN-6 randomised 3,297 participants with type 2 diabetes and reported the primary composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke in 6.6% against 8.9% for placebo over 104 weeks, hazard ratio 0.74 [7]. It also reported a higher rate of retinopathy complications, hazard ratio 1.76, which remains the most-discussed finding of that trial.

SELECT randomised 17,604 participants aged 45 or older with preexisting cardiovascular disease and a body-mass index of 27 or greater, without diabetes. The primary composite occurred in 6.5% against 8.0%, hazard ratio 0.80 [12]. FLOW randomised 3,533 participants with type 2 diabetes and chronic kidney disease and reported a 24% lower risk of the composite kidney outcome, hazard ratio 0.76; it was stopped early at a prespecified interim analysis, which tends to inflate effect estimates [15].

The surrogate-endpoint trials sit alongside these. STEP 1 randomised 1,961 adults without diabetes and reported mean change in body weight at 68 weeks of −14.9% against −2.4% for placebo [9]; STEP 2 examined the same regimen in participants with type 2 diabetes [10]. ESSENCE reported histological endpoints in metabolic dysfunction-associated steatohepatitis at a planned interim in the first 800 of 1,197 participants [17].

Retatrutide — an early record

The phase 1b trial in 72 adults with type 2 diabetes reported a plasma half-life near six days and placebo-adjusted glycated haemoglobin reductions of 1.2% to 1.6% in the three highest groups over 12 weeks; 29 of 72 participants discontinued prematurely [3]. The phase 2 obesity trial randomised 338 adults and reported least-squares mean change in body weight at 48 weeks of −8.7% to −24.2% across the groups against −2.1% for placebo [13]. The phase 2 trial in type 2 diabetes randomised 281 adults and reported glycated haemoglobin change at 24 weeks from −0.43% to −2.02%, against −0.01% for placebo and −1.41% for dulaglutide [14].

A phase 2a substudy in 98 participants reported mean relative change in liver fat at 24 weeks of −42.9% to −82.4% against +0.3% for placebo, measured by imaging rather than histology and with no measure of fibrosis [16]. TRANSCEND-T2D-1, the first phase 3 result, randomised 537 adults and reported mean glycated haemoglobin change of −1.69% to −1.94% against −0.81% for placebo at 40 weeks [19, 24]. The TRIUMPH registrational trials in obesity have completed their primary phases [20, 25].

What can and cannot be said across the two

What can be said is structural. Both programmes report gastrointestinal adverse events as the dominant category, mostly mild to moderate, clustering during escalation, and the leading cause of discontinuation [9, 13, 19]. Both report that the anthropometric change observed in populations with type 2 diabetes is smaller than in populations without it [10, 14].

What cannot be said is anything quantitative. STEP 1 ran 68 weeks; the retatrutide phase 2 obesity trial ran 48 and was designed to characterise the relationship between the amount administered and the response rather than to establish a maximum. SELECT counted cardiovascular events over a mean follow-up of 39.8 months; no comparable retatrutide trial has reported. A difference between two numbers drawn from trials of that different a shape measures the trials, not the compounds.

What the preclinical research shows

Animal research

The two rodent literatures answer different questions, which is itself informative.

The semaglutide rodent work asked where the compound acts. In rats it did not cross the blood-brain barrier, yet still reached the brainstem, septal nucleus and hypothalamus through the circumventricular organs — the places where the barrier is anatomically incomplete. Central c-Fos activation was mapped across ten brain areas, including secondary regions with no direct receptor interaction, and analysis pointed to neurons of the lateral parabrachial nucleus. Body-mass reduction occurred without a decrease in whole-body metabolic rate [8].

The retatrutide rodent work asked what each receptor arm contributes. In diet-induced obese mice the body-mass reduction separated into a decrease in calorie intake attributable to the GIP and GLP-1 receptor arms and an increase in whole-body metabolic rate attributable to the glucagon receptor arm [2]. That last clause is the direct preclinical contrast with semaglutide, whose rodent characterisation found no such change in metabolic rate [8].

Triple agonism at these three receptors had been explored in rodents well before retatrutide: a rationally designed monomeric triagonist was reported in 2015 [21], and later work characterised successive generations of GLP-1/GIP/glucagon triple agonists in obese mice [22].

Findings described in this section were observed in animals, in different laboratories and different model systems. Nothing in them establishes anything about humans, and the contrast between the two rodent records is a contrast between two sets of animal experiments.

Where the in vitro pharmacology differs

In vitro research

Semaglutide's receptor affinity was measured at 0.38 ± 0.06 nM at the GLP-1 receptor, approximately three-fold weaker than liraglutide, with substantially higher albumin affinity — the trade the molecule was designed around. The discovery paper attributes stability against enzymatic degradation to substitutions at positions 8 and 34, and albumin affinity to the fatty acid moiety and its linker chemistry, treating them as separable design levers [1].

Retatrutide was characterised across three cloned receptors rather than one: balanced activity at the glucagon and GLP-1 receptors, with relatively greater activity at the GIP receptor [2]. There is no common assay in which the two molecules have been run side by side, so even their shared GLP-1 receptor activity is reported against different reference standards in different formats. Potency at a cloned receptor in a transfected cell line is not a proportional predictor of tissue effect in any case, and the albumin binding that defines both molecules is absent from the assay.

Research status of each

Semaglutide is an approved medicine in the United States in defined indications, with a published record that includes cardiovascular and kidney outcome trials and a phase 3 trial in metabolic dysfunction-associated steatohepatitis [7, 12, 15, 17].

Retatrutide is investigational. No approval exists for any indication. Its phase 3 programme has begun reporting, with TRANSCEND-T2D-1 published in 2026 [19] and the TRIUMPH registrational trials having completed their primary phases [20].

Every trial named on this page studied pharmaceutical-grade investigational material, manufactured to a regulatory standard, administered under a registered protocol in a defined population under clinical supervision. None of it is research into, or evidence about, research-grade material supplied for laboratory use.

Frequently Asked Questions

What is the difference between retatrutide and semaglutide?
The number of receptors. Semaglutide is an agonist at one receptor, the glucagon-like peptide-1 receptor [1]. Retatrutide is an agonist at three — the GIP, GLP-1 and glucagon receptors [2]. Both are acylated peptides that bind serum albumin reversibly, which is what gives each a plasma half-life measured in days rather than minutes.
Has retatrutide been compared directly with semaglutide in a trial?
No. No registered study has randomised participants between the two. The retatrutide phase 2 trial in type 2 diabetes used dulaglutide 1.5 mg as its active comparator [14], and the remaining published retatrutide trials were placebo-controlled [13, 19]. Semaglutide has been studied head-to-head against tirzepatide [11, 18], but not against retatrutide.
Why is the glucagon receptor the important difference?
Because it acts in a different tissue and in the opposite direction on glucose. Glucagon receptor signalling, most consequentially in liver, raises whole-body metabolic rate and also raises blood glucose when unopposed, which is why glucagon agonism was historically excluded from diabetes research [6]. The reported design premise for retatrutide is that its two incretin arms offset that liability inside the same molecule [2].
Which compound has the deeper published evidence base?
Semaglutide, and the difference is one of category rather than degree. Semaglutide has reported clinical-outcome trials counting cardiovascular events and kidney failure in 3,297, 17,604 and 3,533 participants [7, 12, 15]. Retatrutide has reported no outcome trial; its published endpoints are laboratory and anthropometric measures, plus one 40-week phase 3 glycaemic endpoint [19]. A surrogate endpoint and a clinical outcome are different kinds of evidence.
Is either compound FDA approved?
Semaglutide is an approved medicine in the United States in defined indications. Retatrutide is not approved for any indication. Approval in the United States is specific to a compound and an indication, so nothing about semaglutide's status extends to retatrutide.
What did the animal research find about each?
Different things, because the two rodent literatures asked different questions. Rat work on semaglutide mapped where the compound acts, finding that it reached brainstem and hypothalamic regions through the circumventricular organs without crossing the blood-brain barrier, and that body-mass reduction occurred without a decrease in whole-body metabolic rate [8]. Mouse work on retatrutide separated the contribution of each receptor arm, attributing an increase in whole-body metabolic rate to the glucagon receptor [2]. Findings in animals establish nothing about humans.
Can the trial percentages for the two compounds be compared directly?
No. The trials differ in duration, population, comparator and escalation schedule — STEP 1 ran 68 weeks against placebo in participants without diabetes [9], while the retatrutide phase 2 obesity trial ran 48 weeks and was designed to characterise the relationship between the amount administered and the response [13]. Published systematic analyses of approved incretin mimetics note that indirect comparison rests on assumptions head-to-head randomisation does not require [23].

References

  1. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide Journal of Medicinal Chemistry; 2015. PMID 26308095 doi:10.1021/acs.jmedchem.5b00726
  2. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept Cell Metabolism; 2022. PMID 35985340 doi:10.1016/j.cmet.2022.07.013
  3. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial The Lancet; 2022. PMID 36354040 doi:10.1016/S0140-6736(22)02033-5
  4. The physiology of glucagon-like peptide 1 Physiological Reviews; 2007. PMID 17928588 doi:10.1152/physrev.00034.2006
  5. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain Endocrinology; 1993. PMID 8243312 doi:10.1210/endo.133.6.8243312
  6. Expression cloning and signaling properties of the rat glucagon receptor Science; 1993. PMID 8384375 doi:10.1126/science.8384375
  7. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes The New England Journal of Medicine; 2016. PMID 27633186 doi:10.1056/NEJMoa1607141
  8. Semaglutide lowers body weight in rodents via distributed neural pathways JCI Insight; 2020. PMID 32213703 doi:10.1172/jci.insight.133429
  9. Once-Weekly Semaglutide in Adults with Overweight or Obesity The New England Journal of Medicine; 2021. PMID 33567185 doi:10.1056/NEJMoa2032183
  10. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial The Lancet; 2021. PMID 33667417 doi:10.1016/S0140-6736(21)00213-0
  11. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes The New England Journal of Medicine; 2021. PMID 34170647 doi:10.1056/NEJMoa2107519
  12. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes The New England Journal of Medicine; 2023. PMID 37952131 doi:10.1056/NEJMoa2307563
  13. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial The New England Journal of Medicine; 2023. PMID 37366315 doi:10.1056/NEJMoa2301972
  14. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA The Lancet; 2023. PMID 37385280 doi:10.1016/S0140-6736(23)01053-X
  15. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes The New England Journal of Medicine; 2024. PMID 38785209 doi:10.1056/NEJMoa2403347
  16. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Nature Medicine; 2024. PMID 38858523 doi:10.1038/s41591-024-03018-2
  17. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis The New England Journal of Medicine; 2025. PMID 40305708 doi:10.1056/NEJMoa2413258
  18. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity The New England Journal of Medicine; 2025. PMID 40353578 doi:10.1056/NEJMoa2416394
  19. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial The Lancet; 2026. PMID 42250575 doi:10.1016/S0140-6736(26)00967-0
  20. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Diabetes, Obesity and Metabolism; 2026. PMID 41090431 doi:10.1111/dom.70209
  21. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents Nature Medicine; 2015. PMID 25485909 doi:10.1038/nm.3761
  22. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice Molecular Metabolism; 2022. PMID 35809773 doi:10.1016/j.molmet.2022.101533
  23. Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo-controlled clinical trials Diabetes, Obesity and Metabolism; 2025. PMID 40212008 doi:10.1111/dom.16398
  24. Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise. NCT06354660
  25. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight. NCT05929066

Every identifier above is resolved against PubMed, Crossref or ClinicalTrials.gov at build time, and the title returned by the register is compared with the title stored here. A page does not publish if a reference fails to resolve.

Research-Use Information

For in vitro research use only. This material is a laboratory reagent. It is not a drug, food, dietary supplement, or cosmetic and is not for human or veterinary use, including ingestion, injection, or any other administration. No information on this page describes or implies any effect in humans or animals. Sold only to researchers under our Terms of Sale.